✦ LIBER ✦

Randomized trial or the selective aromatase inhibitor formestane (Lentaron®) versus tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer

✍ Scribed by R. Peréz-Carrion; V. Alberola; F. Calabresi; R-Th. Michel; R. Santos; M. Fehling; C.M. Royce; P.F. Trunet

Book ID: 113404319
Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 298 KB
Volume: 2
Category: Article
ISSN: 0960-9776
DOI: 10.1016/0960-9776(93)90119-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

68. Randomized trial between the selecti

68. Randomized trial between the selective aromatase inhibitor formestane (Lentaron) or tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer: confirmation of bioequivalence in survival

✍ C.M. Royce; L. Mauriac; R. Pérez Carrion; V. Alberola; F. Calabresi; R.Th. Miche 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 148 KB

365 Randomized trial between selective a

365 Randomized trial between selective aromatase inhibitor formestane (®lentaron) vs tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer: Confirmation of bioequivalence in survival

✍ L. Mauriac; R. Pérez Carrion; V. Alberola; F. Calabresi; R.Th. Michel; R. Santos 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 153 KB

New aromatase inhibitors as second-line

New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma : A pooled analysis of the randomized trials

✍ Paolo Carlini; Emilio Bria; Diana Giannarelli; Gianluigi Ferretti; Alessandra Fe 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 2 views

Anastrozole (‘Arimidex’) versus tamoxife

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

✍ Beat Thürlimann; Dagmar Hess; Dieter Köberle; Isabella Senn; Pierluigi Ballabeni 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 348 KB

Exemestane versus anastrozole as front-l

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer : Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

✍ Antonio Llombart-Cussac; Amparo Ruiz; Antonio Antón; Agustí Barnadas; Silvia Ant 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

Randomized Phase III Placebo-Controlled

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

✍ Wolff, A. C.; Lazar, A. A.; Bondarenko, I.; Garin, A. M.; Brincat, S.; Chow, L.; 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 194 KB